Clinical Trials

Darolutamide, an investigational androgen receptor inhibitor, significantly improved metastasis-free survival in men with high-risk nonmetastatic castration-resistant prostate cancer (CRPC) compared with placebo in a large phase 3 clinical trial.
Dr James provides a review of recent report from the American Cancer Society Cancer Action Network on barriers to patient enrollment in therapeutic clinical trials for cancer and the consensus recommendations for overcoming these challenges.
Patient navigators are increasingly recognized for their critical role in helping patients make their way through complex healthcare systems, all the way from screening to treatment adherence. Clinical trials are a vital part of high-quality cancer care, and navigators have become invaluable in facilitating patient awareness and access to trials, while also normalizing the clinical trial process and dispelling myths.
Ms Shockney discusses the importance of clinical trials and extends an invitation to apply to the AONN+ Clinical Trials Committee.
The co-chairs of the AONN+ Clinical Trials Committee discuss the roles of navigators and researchers in clinical trials, barriers to clinical trials that navigators can mitigate, and helpful tips and talking points to consider when talking about clinical trials with patients.
In her presentation at the East Coast Regional Meeting of the Academy of Oncology Nurse & Patient Navigators, Ms Wendy Porter discussed regulations related to insurance coverage of clinical trials and how to remove barriers to such coverage.
The following clinical trials are currently recruiting patients with myelodysplastic syndrome for inclusion in a variety of studies targeting a specific subpopulation of patients with this syndrome. Each trial description includes the NLM Identifier to use as a reference with ClinicalTrials.gov. The information below can help oncology nurse navigators direct their appropriate patients to a specific clinical trial described here.
The following clinical trials are currently recruiting patients with renal-cell carcinoma for inclusion in several investigations. Each trial description includes the NLM Identifier to use as reference with ClinicalTrials.gov.
The following clinical trials are currently recruiting patients with cancer for inclusion in several investigations. Each trial description includes the NLM Identifier to use as reference with ClinicalTrials.gov.
Page 2 of 3
Results 11 - 20 of 24

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country